Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| |  Online-Ressource |
|---|
| Verfasst von: | Farid, Kiavasch [VerfasserIn]  |
|---|
| | Sauer, Tim [VerfasserIn] |
|---|
| | Schmitt, Michael [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Schmitt, Anita [VerfasserIn] |
|---|
| Titel: | Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis |
|---|
| Verf.angabe: | Kiavasch Mohammad Nejad Farid, Tim Sauer, Michael Schmitt, Carsten Müller-Tidow and Anita Schmitt |
|---|
| Jahr: | 2024 |
|---|
| Umfang: | 17 S. |
|---|
| Fussnoten: | Gesehen am 08.05.2024 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 16(2024), 1, Artikel-ID 58, Seite 1-17 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Purpose: We aimed to identify subsets of patients who benefit from emergency LA and to establish a therapeutic algorithm for AML patients with hyperleukocytosis. Methods: In this single-center retrospective cohort study, a total of 20 consecutive patients underwent LA because of their clinical symptoms. Overall survival (OS) analysis was conducted using the Kaplan-Meier plot method. Univariate and multivariate analyses (using multiple logistic regression) were performed. At the time of diagnosis, all patients received a standard diagnostic workup for AML including FLT3-ITD mutational analysis. Results: FLT3-ITD mut AML patients receiving LA had a median OS of 437 days (range 5-2379 days) with a corresponding 14-day survival of 92.3%, while FLT3 wt AML patients displayed a significantly lower median OS of only 5 days (range 1-203 days) with a corresponding 14-day survival of 14.3% (p = 0.0001). Conclusions: Among patients with clinical symptoms of leukostasis, the subset of FLT3-ITD mut AML patients showed a better outcome with lower early mortality after emergency LA. Based on these observations, we established a therapeutic algorithm for AML patients with hyperleukocytosis. |
|---|
| DOI: | doi:10.3390/cancers16010058 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/cancers16010058 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/16/1/58 |
|---|
| | DOI: https://doi.org/10.3390/cancers16010058 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | acute myeloid leukemia |
|---|
| | cytoreduction |
|---|
| | early mortality |
|---|
| | hyperleukocytosis |
|---|
| | leukapheresis |
|---|
| | leukostasis |
|---|
| K10plus-PPN: | 1888155191 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis / Farid, Kiavasch [VerfasserIn]; 2024 (Online-Ressource)
69212381
